Xeris Biopharma (NASDAQ:XERS) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Xeris Biopharma (NASDAQ:XERS) announced its quarterly earnings data on Thursday. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03, FiscalAI reports. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The business had revenue of $107.23 million during the quarter, compared to analyst estimates of $101.68 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Xeris reported third-quarter revenue of $107.2 million, up 44% year over year, and raised 2026 revenue guidance to $395 million–$405 million. Management also raised its 2030 revenue outlook from $750 million to more than $1 billion.
• Recorlev revenue nearly doubled year over year to $71.5 million, with record referrals and patient starts following the expanded commercial team’s ramp-up. Management expects momentum to continue, supported by broader screening for hypercortisolism, though access still typically requires prior authorization.
• Gvoke prescriptions rose 5% year over year, but net revenue fell to $21.7 million from $25.2 million a year earlier because of a one-time $4 million Medicaid gross-to-net adjustment. Management said demand improved through the quarter and expects the brand to return to growth.
• KEVEYIS generated $13 million in revenue, its fourth consecutive quarter of year-over-year growth, and received a U.S. patent extending protection through at least 2043. The company plans additional investment to find and support more patients.
• Xeris remains on track to start the pivotal Phase III Cornerstone study of XP-8121 by year-end, with topline results expected in late 2028 and a potential 2030 launch. Management cited peak sales potential of $1 billion–$3 billion, although the opportunity depends on successful clinical development.

Xeris Biopharma Stock Up 25.0%

Shares of XERS stock traded up $2.62 during trading on Thursday, hitting $13.08. 12,595,769 shares of the company were exchanged, compared to its average volume of 2,078,513. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $13.74. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -118.91 and a beta of 0.61. The business’s 50-day simple moving average is $9.40 and its 200 day simple moving average is $7.55.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Xeris reported third-quarter adjusted earnings of $0.06 per share, above analysts’ consensus of $0.03, while revenue of $107.23 million also topped the roughly $101.68 million estimate. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: CEO comments indicated that Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected, strengthening the growth outlook for the company’s commercial portfolio. CEO sees Recorlev nearing $1B in annual sales earlier than expected
• Neutral Sentiment: Xeris updated its FY 2030 earnings guidance, but the provided information does not include the new figures, making the impact difficult to assess.
• Negative Sentiment: Several insiders reported sales totaling 45,000 shares at $10.23 per share. The trades were made under pre-arranged Rule 10b5-1 plans, and the sellers retained substantial holdings, which may temper concern about the transactions.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $255,750.00. Following the sale, the insider owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. This trade represents a 2.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider directly owned 1,614,208 shares of the company’s stock, valued at approximately $16,142,080. This trade represents a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 148,332 shares of company stock valued at $1,409,221 in the last quarter. Insiders own 4.35% of the company’s stock.

Analysts Set New Price Targets

XERS has been the topic of several recent research reports. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Barclays boosted their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Leerink Partners raised their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Xeris Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $13.20.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.